纳米载体
药品
生物利用度
靶向给药
炎症性肠病
药物输送
药理学
多糖
医学
胃肠道
化学
疾病
内科学
生物化学
有机化学
作者
Mingxiao Cui,Min Zhang,Kehai Liu
标识
DOI:10.1016/j.carbpol.2021.118530
摘要
Drugs such as immunosuppressants and glucocorticoids used for the treatment of inflammatory bowel disease (IBD) have certain troubling side effects. Polysaccharide-based nanocarriers with high safety and bioavailability are often used in the construction of colon-targeted drug nanodelivery systems (DNSs). It can help the drug resist the harsh environment of gastrointestinal tract, improve stability and concentrate on the intestinal inflammation regions as much as possible, which effectively reduces drug side effects and enhances its bioavailability. Certain polysaccharides, as prebiotics, can not only endow DNSs with the ability to target the colon based on enzyme responsive properties, but also cooperate with drugs to alleviate IBD due to its good anti-inflammatory activity and intestinal microecological regulation. The changes in the gastrointestinal environment of patients with IBD, the colon-targeted drug delivery process of polysaccharide-based nanocarriers and its synergistic treatment mechanism for IBD were reviewed. Polysaccharides used in polysaccharide-based nanocarriers for IBD were summarized.
科研通智能强力驱动
Strongly Powered by AbleSci AI